These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32571992)

  • 21. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
    Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
    Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
    Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
    Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
    Golshayan AR; Brick AJ; Choueiri TK
    Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
    Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
    Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
    Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
    Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
    Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma.
    Panda A; de Cubas AA; Stein M; Riedlinger G; Kra J; Mayer T; Smith CC; Vincent BG; Serody JS; Beckermann KE; Ganesan S; Bhanot G; Rathmell WK
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
    Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
    Teo MY; Bambury RM; Zabor EC; Jordan E; Al-Ahmadie H; Boyd ME; Bouvier N; Mullane SA; Cha EK; Roper N; Ostrovnaya I; Hyman DM; Bochner BH; Arcila ME; Solit DB; Berger MF; Bajorin DF; Bellmunt J; Iyer G; Rosenberg JE
    Clin Cancer Res; 2017 Jul; 23(14):3610-3618. PubMed ID: 28137924
    [No Abstract]   [Full Text] [Related]  

  • 33. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
    Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
    Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.
    Chehrazi-Raffle A; Meza L; Alcantara M; Dizman N; Bergerot P; Salgia N; Hsu J; Ruel N; Salgia S; Malhotra J; Karczewska E; Kortylewski M; Pal S
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
    García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
    BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
    Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas.
    Ito K
    Int J Urol; 2019 Sep; 26(9):868-877. PubMed ID: 31183903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
    Go H; Kang MJ; Kim PJ; Lee JL; Park JY; Park JM; Ro JY; Cho YM
    Pathol Oncol Res; 2019 Jan; 25(1):51-58. PubMed ID: 28963640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.